Brokerages expect Denali Therapeutics Inc (NASDAQ:DNLI) to post $10.86 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Denali Therapeutics’ earnings, with estimates ranging from $1.20 million to $23.50 million. Denali Therapeutics posted sales of $1.20 million in the same quarter last year, which suggests a positive year-over-year growth rate of 805%. The firm is expected to announce its next quarterly earnings results on Thursday, November 14th.
On average, analysts expect that Denali Therapeutics will report full-year sales of $33.72 million for the current year, with estimates ranging from $10.79 million to $83.79 million. For the next fiscal year, analysts forecast that the firm will report sales of $54.60 million, with estimates ranging from $10.79 million to $175.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Denali Therapeutics.
Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.15). Denali Therapeutics had a negative net margin of 40.78% and a negative return on equity of 11.03%. The company had revenue of $4.20 million during the quarter, compared to the consensus estimate of $4.52 million.
A number of equities analysts have recently issued reports on the stock. Nomura assumed coverage on shares of Denali Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $35.00 price objective for the company. TheStreet cut shares of Denali Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, June 13th. Wedbush assumed coverage on shares of Denali Therapeutics in a research note on Wednesday, September 25th. They issued a “neutral” rating and a $19.00 price objective for the company. They noted that the move was a valuation call. BTIG Research assumed coverage on shares of Denali Therapeutics in a research note on Friday, August 9th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 27th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $27.25.
Shares of DNLI stock traded up $0.39 during mid-day trading on Thursday, reaching $15.20. The company’s stock had a trading volume of 192,494 shares, compared to its average volume of 352,003. Denali Therapeutics has a 1-year low of $13.78 and a 1-year high of $28.86. The company has a market cap of $1.46 billion, a P/E ratio of -38.97 and a beta of 2.15. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.66 and a current ratio of 10.65. The firm’s 50-day moving average is $17.38 and its two-hundred day moving average is $20.51.
In related news, CEO Ryan J. Watts sold 8,581 shares of the stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $18.05, for a total transaction of $154,887.05. Following the completion of the sale, the chief executive officer now owns 12,505 shares in the company, valued at approximately $225,715.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Alexander O. Schuth sold 7,500 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.16, for a total transaction of $136,200.00. In the last 90 days, insiders sold 23,581 shares of company stock valued at $432,162. Corporate insiders own 21.20% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. TD Asset Management Inc. increased its position in shares of Denali Therapeutics by 2.2% during the 1st quarter. TD Asset Management Inc. now owns 23,400 shares of the company’s stock worth $543,000 after purchasing an additional 500 shares in the last quarter. Virtus ETF Advisers LLC increased its position in shares of Denali Therapeutics by 7.9% during the 2nd quarter. Virtus ETF Advisers LLC now owns 14,246 shares of the company’s stock worth $296,000 after purchasing an additional 1,045 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Denali Therapeutics by 19.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,170 shares of the company’s stock worth $271,000 after purchasing an additional 2,101 shares in the last quarter. Swiss National Bank increased its position in shares of Denali Therapeutics by 2.0% during the 2nd quarter. Swiss National Bank now owns 114,800 shares of the company’s stock worth $2,383,000 after purchasing an additional 2,300 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in shares of Denali Therapeutics by 19.3% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 20,555 shares of the company’s stock worth $427,000 after purchasing an additional 3,330 shares in the last quarter. Institutional investors and hedge funds own 73.91% of the company’s stock.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Further Reading: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.